retatrutide trial status vs Tirzepatide: GLP-1, GIP & Glucagon Retatrutide Phase 3: TRIUMPH Program

The fact that monotreme GLP-1 is also expressed in monotreme venom raises the possibility that DPP-4 resistance is selected for when GLP-1 like molecules are recruited into venom function

The body fat loss was maintained after a single dose up to day 43 and its pharmacokinetic characteristics suggested it may be used once a week

MOTS-c is added at Week 5 at 5 mg, 2-3 times per week

Frequently asked questions Can I take vitamin B12 while on Retatrutide

Any suspected side effects from medicines should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk

As of 2026, Retatrutide (LY3437943) is investigational in Phase 3 development and not approved by any regulator